4.5 Article

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future

Journal

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 79, Issue 2, Pages 182-194

Publisher

WILEY
DOI: 10.1111/bcp.12403

Keywords

adherence; antiretroviral; drug interactions; human immunodeficiency virus; pharmacogenomics; therapeutic drug monitoring

Funding

  1. ViiV Healthcare
  2. Janssen
  3. Merck Pty Ltd
  4. Gilead
  5. AbbVie
  6. Bristol Myers Squibb

Ask authors/readers for more resources

The evolution of human immunodeficiency virus (HIV) treatment has improved our understanding and management of complex pharmacological issues that have driven improved outcomes and quality of life of the HIV-infected patient. These issues include adherence, long- and short-term toxicities, pharmacoenhancement, pharmacogenomics, therapeutic drug monitoring, differential penetration of drugs into sanctuary sites, such as the central nervous system, genital tract and small bowel, and drug-drug and drug-food interactions related to cytochrome P450 drug-metabolizing enzymes, uridine diphosphate glucuronyltransferases and drug transporters, to name a few. There is future promise, as an increased understanding of the immunopathogenesis of HIV and global public health initiatives are driving novel treatment approaches with goals to prevent, control and, ultimately, eradicate HIV.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available